PL2110126T3 - Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej - Google Patents
Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnejInfo
- Publication number
- PL2110126T3 PL2110126T3 PL08007640T PL08007640T PL2110126T3 PL 2110126 T3 PL2110126 T3 PL 2110126T3 PL 08007640 T PL08007640 T PL 08007640T PL 08007640 T PL08007640 T PL 08007640T PL 2110126 T3 PL2110126 T3 PL 2110126T3
- Authority
- PL
- Poland
- Prior art keywords
- active ingredient
- liquid
- fluorised
- instillative
- inhalative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08007640A EP2110126B9 (de) | 2008-04-18 | 2008-04-18 | Inhalative und instillative Verwendung von semifluorierten Alkanen als Wirkstoffträger im intrapulmonalen Bereich |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2110126T3 true PL2110126T3 (pl) | 2012-04-30 |
Family
ID=39708796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08007640T PL2110126T3 (pl) | 2008-04-18 | 2008-04-18 | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8986738B2 (pl) |
| EP (1) | EP2110126B9 (pl) |
| JP (1) | JP4990929B2 (pl) |
| CN (1) | CN101559229B (pl) |
| AT (1) | ATE532505T1 (pl) |
| AU (1) | AU2009201137A1 (pl) |
| BR (1) | BRPI0900767A2 (pl) |
| CA (1) | CA2662943A1 (pl) |
| DK (1) | DK2110126T3 (pl) |
| ES (1) | ES2377152T3 (pl) |
| MX (1) | MX2009003812A (pl) |
| PL (1) | PL2110126T3 (pl) |
| PT (1) | PT2110126E (pl) |
| TW (1) | TWI417108B (pl) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
| US8513259B2 (en) | 2009-07-03 | 2013-08-20 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
| EP2332525A1 (en) * | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
| EP2335735A1 (en) | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| US10045996B2 (en) | 2010-03-17 | 2018-08-14 | Novaliq Gmbh | Pharmaceutical composition for treatment of increased intraocular pressure |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| TR201901309T4 (tr) * | 2011-01-04 | 2019-02-21 | Novaliq Gmbh | Semiflorlanmış alkanları içeren o/w emülsiyonları. |
| ES2962524T3 (es) | 2011-05-25 | 2024-03-19 | Dermaliq Therapeutics Inc | Composición farmacéutica tópica a base de alcanos semifluorados |
| AU2012260788B2 (en) | 2011-05-25 | 2017-01-19 | Dermaliq Therapeutics, Inc. | Pharmaceutical composition for administration to nails |
| PL2806886T3 (pl) * | 2012-01-23 | 2017-08-31 | Novaliq Gmbh | Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach |
| KR102051677B1 (ko) * | 2012-04-23 | 2019-12-03 | 키에시 파르마슈티시 엣스. 피. 에이. | 분무화에 의한 폐계면활성제의 투여를 위한 방법 및 시스템 |
| PL2895144T3 (pl) | 2012-09-12 | 2017-07-31 | Novaliq Gmbh | Kompozycje semifluorowanych alkanów |
| DK2708228T3 (en) | 2012-09-12 | 2018-08-20 | Novaliq Gmbh | COMPOSITION FOR EYE RINSE |
| CN113952321B (zh) | 2012-09-12 | 2023-03-28 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
| US10273298B2 (en) * | 2013-07-23 | 2019-04-30 | Novaliq Gmbh | Stabilized antibody compositions |
| US11648261B2 (en) * | 2014-05-12 | 2023-05-16 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US10925889B2 (en) * | 2014-05-12 | 2021-02-23 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| CN110403923B (zh) | 2015-09-30 | 2021-09-21 | 诺瓦利克有限责任公司 | 半氟化化合物和其组合物 |
| JP6642935B2 (ja) | 2015-09-30 | 2020-02-12 | ノバリック ゲーエムベーハー | 眼投与用の半フッ素化化合物 |
| CN109640900B (zh) | 2016-06-23 | 2020-07-07 | 诺瓦利克有限责任公司 | 一种试剂盒 |
| CN116172987A (zh) | 2016-09-22 | 2023-05-30 | 诺瓦利克有限责任公司 | 用于治疗睑缘炎的药物组合物 |
| US10813976B2 (en) | 2016-09-23 | 2020-10-27 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| JP7032404B2 (ja) | 2016-12-23 | 2022-03-08 | ノバリック ゲーエムベーハー | ドライアイ疾患の治療のための眼科用組成物 |
| WO2018193093A1 (en) | 2017-04-21 | 2018-10-25 | Novaliq Gmbh | Iodine compositions |
| WO2018202835A1 (en) | 2017-05-05 | 2018-11-08 | Novaliq Gmbh | Process for the production of semifluorinated alkanes |
| CN110650734B (zh) | 2017-05-12 | 2024-11-15 | 诺瓦利克有限责任公司 | 治疗与隐形眼镜有关病症的包含半氟化烷烃的药物组合物 |
| BR112020006072A2 (pt) | 2017-09-27 | 2020-10-06 | Novaliq Gmbh | composições oftalmáticas compreendendo latanoprost para uso no tratamento de doenças oculares |
| US11896559B2 (en) | 2017-10-04 | 2024-02-13 | Novaliq Gmbh | Opthalmic compositions comprising F6H8 |
| US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| JP2021522219A (ja) | 2018-04-27 | 2021-08-30 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| JP7360452B2 (ja) | 2018-09-27 | 2023-10-12 | ダーマリック セラピューティクス， インコーポレーテッド | 脂質バリアの修復 |
| PL3856128T3 (pl) | 2018-09-27 | 2023-10-16 | Dermaliq Therapeutics, Inc. | Formulacja filtra przeciwsłonecznego do stosowania miejscowego |
| CA3112031A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| US12397039B2 (en) | 2019-02-13 | 2025-08-26 | Novaliq Gmbh | Compositions and methods for the treatment of ocular neovascularization |
| US12226478B2 (en) | 2019-04-28 | 2025-02-18 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US11707518B2 (en) | 2019-04-28 | 2023-07-25 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| KR20220058577A (ko) | 2019-09-06 | 2022-05-09 | 노바리크 게엠베하 | 포도막염 치료를 위한 안과용 조성물 |
| DE102021005495A1 (de) | 2021-11-06 | 2023-05-11 | Kocher-Plastik Maschinenbau Gmbh | Trennvorrichtung |
| DE102021005494A1 (de) | 2021-11-06 | 2023-05-11 | Kocher-Plastik Maschinenbau Gmbh | Trennvorrichtung |
| WO2024208750A1 (en) | 2023-04-03 | 2024-10-10 | Dermaliq Therapeutics Gmbh | Tri-azole antifungal compositions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| US5869539A (en) | 1996-04-17 | 1999-02-09 | Board Of Regents, The University Of Texas System | Emulsions of perfluoro compounds as solvents for nitric oxide (NO) |
| US6433040B1 (en) | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| US6585957B1 (en) * | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| WO2005099718A1 (en) | 2004-04-19 | 2005-10-27 | Centre National De La Recherche Scientifique (C.N.R.S.) | Lung surfactant supplements |
| DE102005055811A1 (de) * | 2005-11-23 | 2007-05-31 | Novaliq Gmbh | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
-
2008
- 2008-04-18 PT PT08007640T patent/PT2110126E/pt unknown
- 2008-04-18 EP EP08007640A patent/EP2110126B9/de active Active
- 2008-04-18 DK DK08007640.9T patent/DK2110126T3/da active
- 2008-04-18 AT AT08007640T patent/ATE532505T1/de active
- 2008-04-18 ES ES08007640T patent/ES2377152T3/es active Active
- 2008-04-18 PL PL08007640T patent/PL2110126T3/pl unknown
-
2009
- 2009-03-20 AU AU2009201137A patent/AU2009201137A1/en not_active Abandoned
- 2009-03-27 TW TW098110222A patent/TWI417108B/zh not_active IP Right Cessation
- 2009-03-31 US US12/415,482 patent/US8986738B2/en active Active
- 2009-04-08 MX MX2009003812A patent/MX2009003812A/es active IP Right Grant
- 2009-04-14 BR BRPI0900767-9A patent/BRPI0900767A2/pt not_active IP Right Cessation
- 2009-04-16 CA CA002662943A patent/CA2662943A1/en not_active Abandoned
- 2009-04-17 JP JP2009101019A patent/JP4990929B2/ja active Active
- 2009-04-20 CN CN2009101310362A patent/CN101559229B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ATE532505T1 (de) | 2011-11-15 |
| JP2009256353A (ja) | 2009-11-05 |
| US8986738B2 (en) | 2015-03-24 |
| JP4990929B2 (ja) | 2012-08-01 |
| US20100008996A1 (en) | 2010-01-14 |
| TW200950809A (en) | 2009-12-16 |
| CN101559229B (zh) | 2013-07-31 |
| CN101559229A (zh) | 2009-10-21 |
| ES2377152T9 (es) | 2013-02-18 |
| EP2110126A1 (de) | 2009-10-21 |
| HK1135043A1 (en) | 2010-05-28 |
| PT2110126E (pt) | 2012-02-20 |
| AU2009201137A1 (en) | 2009-11-05 |
| BRPI0900767A2 (pt) | 2010-12-28 |
| EP2110126B1 (de) | 2011-11-09 |
| ES2377152T3 (es) | 2012-03-22 |
| MX2009003812A (es) | 2009-10-19 |
| CA2662943A1 (en) | 2009-10-18 |
| TWI417108B (zh) | 2013-12-01 |
| EP2110126B9 (de) | 2012-09-19 |
| DK2110126T3 (da) | 2012-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2110126T3 (pl) | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej | |
| ES2547336T3 (es) | Composición tópica para su uso para el tratamiento de enrojecimiento inducido por rosácea | |
| Xiao et al. | Hydrogen sulfide improves endothelial dysfunction in hypertension by activating peroxisome proliferator-activated receptor delta/endothelial nitric oxide synthase signaling | |
| AU2012262534B2 (en) | Method of determining vasoreactivity using inhaled nitric oxide | |
| DE602007010807D1 (de) | Vorrichtung für kombinierte behandlung | |
| WO2009097443A3 (en) | Liquid formulations of compounds active at sulfonylurea receptors | |
| WO2008007322A3 (en) | Anti-hemorrhage medication pack | |
| BR112012025047A2 (pt) | formulações líquidas estabilizadas | |
| PE20180203A1 (es) | Procedimiento para la preparacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificacion para su uso como principio activo farmaceutico | |
| UY31406A1 (es) | "producto de dispersion solida que contiene un compuesto a base de n-aril urea". | |
| AR070842A1 (es) | Regimen de dosificacion para un agonista de receptor selectivo de s1p1 | |
| JP2010516689A (ja) | メタボリック症候群治療用の新規組成物 | |
| AR059359A1 (es) | Formulaciones farmaceuticas que contienen pleconaril | |
| JP2023510661A (ja) | 窒素酸化物を生成するための方法及び組成物、並びにそれらの使用 | |
| WO2010103844A1 (ja) | 鎮痛・抗炎症剤含有外用剤 | |
| ECSP24020925A (es) | Profármaco de derivados de pirrolidona como activador de glucocinasa | |
| Chiruvella et al. | Intraperitoneal instillation of ropivacaine plus dexmedetomidine for pain relief after laparoscopic hysterectomy: A comparison with ropivacaine alone | |
| AR065316A1 (es) | Uso de quitosanos, derivados de quitosanos y una sal fisiologiamente aceptable del mismo para el tratamiento de enfermedades inflamatorias ungueales | |
| Fike et al. | Cyclooxygenase contracting factors and altered pulmonary vascular responses in chronically hypoxic newborn pigs | |
| AR059225A1 (es) | Sal de citrato, proceso de preparacion y su actividad en terapia | |
| Hosseinjani et al. | N-acetylcysteine for the prevention of non-contrast media agent-induced kidney injury: from preclinical data to clinical evidence | |
| Kihara et al. | Effect of zenarestat, an aldose reductase inhibitor, on endoneurial blood flow in experimental diabetic neuropathy of rat | |
| DK1716845T3 (da) | Formulering til dermal anvendelse | |
| ECSP12012352A (es) | Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal | |
| D’Auria et al. | Urine retention in a child treated with oral salbutamol |